Herrero-Beaumont Gabriel, Martínez Calatrava María José, Castañeda Santos
Laboratorio de Patología Osteoarticular, Servicio de Reumatología, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
Reumatol Clin. 2012 Mar-Apr;8(2):78-83. doi: 10.1016/j.reuma.2011.08.002. Epub 2011 Nov 21.
The double and simultaneous molecular interaction between antigen-presentig cells (APC) and T lymphocytes is essential for the optimal activation of the immunological response and requires the participation of two membrane receptor groups. Abatacept is a fusion protein that selectively modulates one of these two ways, by binding to CD80 and CD86 receptors on APC. In this way, the drug inhibits T cell activation, selectively blocking the specific interaction of CD80/CD86 receptors to CD28 and, therefore, inhibiting T cell proliferation and B cell immunological response. This pharmacological action results in the normalization of inflammatory mediators in rheumatoid arthritis patients and in a safe and efficacious clinical response. Abatacept in combination with methotrexate prevents the progression of joint damage and improves physical function in rheumatoid arthritis patients.
抗原呈递细胞（APC）与T淋巴细胞之间的双重且同时发生的分子相互作用对于免疫反应的最佳激活至关重要，并且需要两个膜受体组的参与。阿巴西普是一种融合蛋白，它通过与APC上的CD80和CD86受体结合，选择性地调节这两种方式中的一种。通过这种方式，该药物抑制T细胞活化，选择性地阻断CD80/CD86受体与CD28的特异性相互作用，从而抑制T细胞增殖和B细胞免疫反应。这种药理作用导致类风湿性关节炎患者炎症介质正常化，并产生安全有效的临床反应。阿巴西普与甲氨蝶呤联合使用可防止类风湿性关节炎患者关节损伤的进展并改善身体功能。
